Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Optimizing CML Management: Shared Decision Making and Enhancing the Patient Experience : Episode 2

      Navigating CML: Tools to Empower Patients and Caregivers

      July 31, 2024
      By Jorge E. Cortes, MD
      Joannie Clements
      • Claire Saxton

      Opinion
      Video

      Joannie Clements, a patient advocate, provides insights on helping newly diagnosed patients with CML and their caregivers navigate the complexities of diagnosis, and Claire Saxton outlines resources available for them.

      EP: 1.Understanding CML: Your Journey from Diagnosis to Treatment

      Now Viewing

      EP: 2.Navigating CML: Tools to Empower Patients and Caregivers

      EP: 3.Empowering CML Caregivers: Strategies and Support Systems

      EP: 4.Starting CML Treatment: Collaborative Choices for Better Outcomes

      EP: 5.Open Dialogue in CML Care: Setting Expectations, Managing Side Effects, and Optimizing Patient Quality of Life

      EP: 6.When CML Therapy Shifts: Collaborative Approaches to Treatment Changes

      EP: 7.CML Treatment: Scenarios that Necessitate Switching Therapy

      EP: 8.Ensuring Informed CML Care from Diagnosis Onward

      EP: 9.Advancing CML Management Towards an Ideal Patient Journey

      This program was made possible with support from Novartis Pharmaceuticals.

      Video content above is prompted by the following questions:

      • As a patient advocate, how do you help newly diagnosed CML patients and their caregivers navigate the complexities of the diagnosis and set appropriate care goals? What are some of the biggest challenges patients may face at this stage?
      • What resources or educational materials have you found most helpful in supporting newly diagnosed CML patients and their caregivers?
        • How do patients typically use these materials? How have you changed your approaches so patients and caregivers can best leverage these materials?

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      A panel of 3 experts on CML
      A panel of 3 experts on CML
      A panel of 3 experts on CML
      A panel of 3 experts on CML
      A panel of 3 experts on CML
      A panel of 3 experts on CML
      A panel of 3 experts on CML
      A panel of 3 experts on CML
      Related Content

      Image of blood cells

      Fast Track Status Given to Givinostat for Polycythemia Vera

      Tim Cortese
      May 11th 2025
      Article

      The safety and efficacy of givinostat is being assessed vs hydroxyurea in the phase 3 GIV-IN PV trial.


      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      December 14th 2023
      Podcast

      Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.


      Line illustration of red blood cells on a yellow background

      Blinatumomab-Linked ICANS Cases Higher Than Previously Reported

      Russ Conroy
      April 20th 2025
      Article

      Using tools like the ICE Score could improve consistency in grading neurotoxicity tied to bispecific antibodies in hematologic cancers.


      Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

      Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

      Lindsay Fischer
      December 1st 2023
      Podcast

      Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.


      Aerial photo of four medical professionals talking in a huddle; two are wearing scrubs and two are wearing lab coats

      Shared Model of Care Post-HCT Offers Safe Follow-Up, Reduces Patient Burden

      Bridget Hoyt
      Published: March 19th 2025 | Updated: March 19th 2025
      Article

      Alternating post-HCT care between specialized facilities and local cancer centers produced noninferior non-relapse mortality and similar quality of life to usual care.


      light blue background with a white outline indicating blood cells

      Positive Responses to Liso-Cel Observed in Relapsed/Refractory Marginal Zone Lymphoma

      Ashling Wahner
      February 16th 2025
      Article

      Lisocabtagene maraleucel demonstrated a statistically significant overall response rate in adults with relapsed/refractory marginal zone lymphoma.

      Related Content

      Image of blood cells

      Fast Track Status Given to Givinostat for Polycythemia Vera

      Tim Cortese
      May 11th 2025
      Article

      The safety and efficacy of givinostat is being assessed vs hydroxyurea in the phase 3 GIV-IN PV trial.


      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      December 14th 2023
      Podcast

      Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.


      Line illustration of red blood cells on a yellow background

      Blinatumomab-Linked ICANS Cases Higher Than Previously Reported

      Russ Conroy
      April 20th 2025
      Article

      Using tools like the ICE Score could improve consistency in grading neurotoxicity tied to bispecific antibodies in hematologic cancers.


      Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

      Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

      Lindsay Fischer
      December 1st 2023
      Podcast

      Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.


      Aerial photo of four medical professionals talking in a huddle; two are wearing scrubs and two are wearing lab coats

      Shared Model of Care Post-HCT Offers Safe Follow-Up, Reduces Patient Burden

      Bridget Hoyt
      Published: March 19th 2025 | Updated: March 19th 2025
      Article

      Alternating post-HCT care between specialized facilities and local cancer centers produced noninferior non-relapse mortality and similar quality of life to usual care.


      light blue background with a white outline indicating blood cells

      Positive Responses to Liso-Cel Observed in Relapsed/Refractory Marginal Zone Lymphoma

      Ashling Wahner
      February 16th 2025
      Article

      Lisocabtagene maraleucel demonstrated a statistically significant overall response rate in adults with relapsed/refractory marginal zone lymphoma.

      Latest Conference Coverage

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      AI Tool May Predict Response, Resistance in Advanced RCC

      Olanzapine May Reduce Nausea, Vomiting From Radiation

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.